Adele Gulfo
EnproAbout Adele M. Gulfo
Adele M. Gulfo, age 62, has served as an independent director of Enpro Inc. (NPO) since 2018. She holds a B.S. in Biology from Seton Hall University and an M.B.A. in Marketing from Fairleigh Dickinson University, and brings deep commercial, marketing, and biopharma leadership experience, including launching Lipitor at Parke‑Davis/Warner‑Lambert and senior roles at Pfizer, Mylan (Viatris), Sumitovant Biopharma, and Sumitomo Pharma America . The board determined she is independent under NYSE standards; in 2024 each director met at least 75% attendance thresholds and all nominees attended the 2024 annual meeting .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sumitomo Pharma America | Chief Executive Officer, Biopharma Commercial Unit | Jul 2023 – Sep 2024 | Led biopharma commercial unit; executive leadership |
| Sumitovant Biopharma | Chief Business & Commercial Development Officer | Dec 2019 – Sep 2024 | Commercial strategy and development leadership |
| Mylan N.V. (now Viatris) | EVP & Head of Global Commercial Development | Jan 2014 – Jan 2018 | Global commercial development leadership |
| Pfizer Inc. | President & GM, U.S. Primary Care; ran U.S. Commercial Ops & Managed Markets | Not disclosed | Senior U.S. biopharma operations |
| AstraZeneca Pharmaceuticals | Executive positions | Not disclosed | Executive biopharma roles |
| Parke‑Davis/Warner‑Lambert | Senior Director, Cardiovascular Marketing | Not disclosed | Launched Lipitor |
External Roles
| Organization | Role | Tenure | Committee Positions |
|---|---|---|---|
| Tyra Biosciences, Inc. | Director (current) | Not disclosed | Not disclosed |
| Bemis Company, Inc. | Director (prior 5 years) | Not disclosed | Not disclosed |
| Medexus Pharmaceuticals Inc. | Director (prior 5 years) | Not disclosed | Not disclosed |
| Myovant Sciences Ltd. | Director (prior 5 years) | Not disclosed | Not disclosed |
Board Governance
- Committee memberships: Audit & Risk Management, Compensation & Human Resources, and Nominating & Corporate Governance; not a committee chair (chairs: Humphrey—Audit; Botts—Compensation; Reinsdorf—Nominating) .
- Independence: Board affirmed independence of all nominees other than CEO Vaillancourt .
- Attendance: Board met 4 times in 2024; each director attended at least 75% of board and committee meetings; all director nominees attended the 2024 annual meeting .
- Board leadership: Independent Chairman; independent directors meet in executive sessions without management .
Fixed Compensation
| Metric | 2024 |
|---|---|
| Annual cash retainer ($) | $100,000 |
| Committee chair fees ($) | $0 (not a chair) |
| Equity grant (fully vested shares or phantom shares) | 803 shares/phantom shares on Feb 15, 2024 |
| Equity grant reported fair value ($) | $132,423 |
| Dividend‑equivalent phantom shares (grant date fair value) ($) | $4,939 |
| Total director compensation ($) | $237,361 |
| Phantom shares held (to be settled in shares) (#) | 4,042 |
- Program structure: Non‑employee directors receive $100,000 cash retainer and ~$125,000 equity annually; phantom shares fully vested at award and paid in shares upon board departure; chair fees only for committee chairs and independent Chairman .
Performance Compensation
- Directors do not have performance‑based pay; annual equity grants are fully vested (no TSR/financial metrics for directors) .
| Performance metrics tied to director compensation | None disclosed |
Other Directorships & Interlocks
- Current public board: Tyra Biosciences, Inc. .
- Prior 5 years: Bemis Company, Inc.; Medexus Pharmaceuticals Inc.; Myovant Sciences Ltd. .
- Related‑party/interlocks at Enpro: Only Excelitas transactions (approx. $423,000) disclosed via committee member Ronald Keating; board concluded non‑material; no related‑party transactions involving Ms. Gulfo disclosed .
Expertise & Qualifications
- Extensive commercial development, marketing, and general management across global pharma markets; experience in strategy, commercial transformations, efficiency, and engagement .
- Matrix highlights applicable skills in end‑markets, international experience, M&A/business development, sales/marketing, and senior leadership .
Equity Ownership
| Metric | As of Mar 3, 2025 |
|---|---|
| Beneficial ownership (shares) | 9,020 |
| Ownership as % of shares outstanding | <1% (21,041,682 shares outstanding) |
| Shares “may acquire within 60 days” via phantom awards (payable in shares upon board departure) | 4,727 |
| Phantom shares held (to be settled in shares) | 4,042 |
| Director stock units (deferred cash retainer) | None listed for Ms. Gulfo |
| Stock ownership guideline | 5× annual retainer; compliance verified for directors serving ≥5 years (incl. Gulfo) as of Feb 13, 2025 |
| Pledging/Hedging | Prohibited by policy |
Governance Assessment
- Alignment: Independent director on three key committees; ownership guideline compliance and anti‑pledging/anti‑hedging policies support alignment with shareholders .
- Engagement: Board/committee self‑evaluations; independent executive sessions; strong say‑on‑pay support (94.6% at 2024 meeting) signals investor confidence in pay oversight .
- Compensation structure: Standard director pay mix (cash retainer + fully‑vested equity); no performance metrics or perquisites—reduces incentive misalignment risk .
- Conflicts and interlocks: No related‑party transactions disclosed for Ms. Gulfo; board reaffirmed independence; only Keating’s Excelitas customer relationship disclosed and deemed immaterial .
- RED FLAGS: None disclosed specific to Ms. Gulfo (no pledging/hedging; no related‑party transactions; attendance thresholds met) .